2054 Immune Checkpoints Inhibitor

Gender Neutral
Type Module
Testing Phase II / II - in development
Principal investigator(s)
Mieke Van Hemelrijck
Principal Investigator
King's College London
London, United Kingdom
, Marieke van Leeuwen
Principal Investigator
The Netherlands Cancer Institute
Study coordinator(s)
Louis Fox
Principal Investigator
King’s College London
London, United Kingdom

Project summary

This project aims to determine the need for additional EORTC quality of life measures that are specific to cancer patients receiving immune checkpoint inhibitors. If a need is identified, the project will produce a provisional immune checkpoint inhibitor module or item list which will then undergo further testing and validation. The project will also identify whether patients on different types of immune checkpoint inhibitor treatment regimens require different items to query their quality of life, and similar for patients experiencing different types of cancers.


The project is currently in the literature review stage, which so far has involved the examination of more than 600 review articles potentially related to quality of life issues in patients receiving immune checkpoint inhibitors.

Phase 1 – not yet recruiting.

Future plans

Phase 1 of this project consists of two stages: Phase 1a and Phase 1b. Following the literature review, recruitment for Phase 1a is expected to begin in January 2022. Recruitment for Phase 1b is expected to begin in November 2022. Phase 2 of the project is expected to commence in September 2023, with Phases 1 and 2 of the project concluded by January 2024.

For patients

This project aims to produce a list of scientifically valid questions that can measure the quality of life of cancer patients undergoing a type of treatment called immunotherapy. Being able to measure patients’ quality of life is important for clinicians and researchers to develop and provide treatments for patients which allow them to have the best possible quality of life.